Blood distribution and single-dose pharmacokinetics of leflunomide.

Therapeutic Drug Monitoring
J LucienR W Yatscoff

Abstract

Leflunomide (HWA 486, LEF) is a novel isoxazole derivative with potent immunosuppressive properties. LEF is converted to its active metabolite (A77 1726) after absorption. Presently, the blood distribution and pharmacokinetics of LEF have not been reported. Such information would prove invaluable in determining the appropriate medium for analysis and optimal immunosuppressive dosing regimes. In this study, A77 1726 was found to be primarily associated (> 95%) with the lipoprotein free fraction of plasma at all tested concentrations ranging from 0.4 to 100 mg/L. Detectable levels of A77 1726 (0.34 +/- 0.18 mg/L), analyzed by HPLC, were found in the plasma free fraction only at the highest tested concentration (100 mg/L). Single-dose pharmacokinetics of A77 1726 (i.v.) and HWA 486 (p.o.) were investigated in five healthy New Zealand white rabbits. The half-lives (t1/2) of A77 1726 i.v. and HWA 486 p.o. administration were 3.88 +/- 2.3 and 3.18 +/- 1.6 h, respectively. The volume of distribution by both routes of administration indicates minimal distribution into tissues (Vdss p.o. = 0.14 +/- 0.03 L/kg and Vdssi.v. = 0.09 +/- 0.02 L/kg). The mean residence time of A77 1726 was greater after oral administration of LEF (MRTp.o. = 10...Continue Reading

Citations

Nov 28, 2012·Clinical Rheumatology·Raoul BergnerChristian Löffler
May 1, 1997·The American Journal of the Medical Sciences·H T Silva Júnior, R E Morris
Sep 30, 2010·Immunotherapy·Sven Teschner, Volker Burst
Jun 5, 2003·Expert Opinion on Pharmacotherapy·Corinne Miceli-Richard, Maxime Dougados
Jan 1, 1997·Expert Opinion on Investigational Drugs·H T Silva, R E Morris
May 28, 2011·Journal of Veterinary Pharmacology and Therapeutics·M L MehlC R Gregory
Aug 23, 2005·Journal of Pharmaceutical and Biomedical Analysis·Duygu YeniceliMuzaffer Tuncel
Jul 24, 1998·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·T UhligP D Sly
May 27, 2004·World Journal of Gastroenterology : WJG·Hong-Wei YaoShu-Yun Xu
Jan 31, 2002·The Annals of Pharmacotherapy·Jasmine M BeamanKenneth F Illett
Jun 11, 1999·Journal of the American Society of Nephrology : JASN·J F GummertR E Morris

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.